

Daphne W Dumoulin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/276862/publications.pdf>

Version: 2024-02-01

15
papers

976
citations

1040056

9
h-index

996975

15
g-index

15
all docs

15
docs citations

15
times ranked

1670
citing authors

#	ARTICLE	IF	CITATIONS
1	Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium. <i>European Journal of Cancer</i> , 2022, 160, 261-272.	2.8	7
2	SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC).. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA8507-LBA8507.	1.6	46
3	Lurbinectedin shows clinical activity and immune-modulatory functions in patients with pre-treated small cell lung cancer and malignant pleural mesothelioma. <i>European Journal of Cancer</i> , 2022, 172, 357-366.	2.8	4
4	High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients. <i>European Journal of Cancer</i> , 2021, 144, 41-48.	2.8	64
5	Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials. <i>Vaccines</i> , 2021, 9, 525.	4.4	13
6	ETV6-NTRK3 translocation-associated low-grade mucinous bronchial adenocarcinoma: A novel bronchial salivary gland-type non-small cell lung cancer subtype. <i>Lung Cancer</i> , 2021, 156, 72-75.	2.0	6
7	Immunotherapy in small cell lung cancer: one step at a time: a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 2970-2987.	2.8	11
8	Defining oligometastatic non-small cell lung cancer: concept versus biology, a literature review. <i>Translational Lung Cancer Research</i> , 2021, 10, 3329-3338.	2.8	10
9	Phase II trial of natalizumab for the treatment of anti-Hu associated paraneoplastic neurological syndromes. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaab145.	0.7	3
10	Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program. <i>Translational Lung Cancer Research</i> , 2020, 9, 1169-1179.	2.8	30
11	Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study. <i>European Journal of Cancer</i> , 2020, 141, 171-184.	2.8	65
12	A brief report on combination chemotherapy and anti-“programmed death (ligand) 1 treatment in small-cell lung cancer: Did we choose the optimal chemotherapy backbone?. <i>European Journal of Cancer</i> , 2020, 137, 40-44.	2.8	5
13	Renal Toxicity From Pemetrexed and Pembrolizumab in the Era of Combination Therapy in Patients With Metastatic Nonsquamous Cell NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1472-1483.	1.1	32
14	Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-“Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2019, 5, 1276.	7.1	670
15	Is immunotherapy a viable option in treating mesothelioma?. <i>Future Oncology</i> , 2017, 13, 1747-1750.	2.4	10